Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426

Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Tom Waddell,Dmitry Nosov,Frederic Pouliot,Boris Alekseev,Denis Soulieres,Bohuslav Melichar,Ihor O. Vynnychenko,Sergio Jobim Azevedo,Delphine Borchiellini,Raymond S. McDermott,Jens Bedke,Satoshi Tamada, Sterling Wu,Joseph Burgents,L. Rhoda Molife,Thomas Powles

JOURNAL OF CLINICAL ONCOLOGY（2023）

Cited 73|Views73
No score
Abstract
5001Background: The randomized, open-label, phase 3 KEYNOTE-426 study (NCT02853331) demonstrated that pembrolizumab (pembro) + axitinib (axi) significantly improved OS, PFS, and ORR vs sunitinib as...
More
Translated text
Key words
advanced renal cell carcinoma,axitinib,sunitinib,first-line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined